| BIOMARIN PHAR. DL-,001 | 64.74 / +0.03% |
| Date/Time | 04/13 / 22:59 |
| Chg. / Chg.(%) | 0.02 / +0.03% |
| Bid | 64.74 |
| Ask | 65.54 |
| Open | 64.72 |
| Previous Close | 64.72 |
| High | 65.52 |
| Low | 63.86 |
| Volume [EUR] | - |
| Volume [Units] | |
| Price fixings | 4612 |
| ISIN | US09061G1013 |
| Security | BM8 |
| Exchange | Lang & Schwarz |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| NASDAQ | 77.7700 |  |
863,490 |
| IEX | 77.78 | |
17,101 |
| Cboe US | 77.80 | |
13,089 |
| Vienna Globa.. | 64.72 | |
473 |
| TradeGate | 64.220 | |
401 |
| Frankfurt | 64.7600 | |
8 |
| Xetra | 64.72 | |
0 |
| Berlin | 64.68 | |
0 |
| München | 64.82 | |
0 |
| Düsseldorf | 64.12 | |
0 |
| Stuttgart | 64.880 | |
0 |
| Lang & Schwa.. | 64.74 | |
|
| gettex | 65.020 | |
|
| Mexico | 1,555.62 | |
647 |
| London Inter.. | 49.40 | 491 |
News
- BioMarin sinks 32% as FDA delays its hemophilia treatment
08/19/2020 / 16:23 - TeleTrader - Nasdaq turns red as pharma stocks fall
04/28/2020 / 16:48 - TeleTrader - BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia
12/12/2016 / 14:29 - GlobeNewswire - NICE Recommends BioMarin's Vimizim® (elosulfase alfa) for the Treatment of Morquio A Syndrome in England
11/23/2015 / 16:59 - GlobeNewswire
Real-time